VQW 765
Alternative Names: AQW-051; JQH481R778; VQW-765Latest Information Update: 12 Nov 2025
At a glance
- Originator Novartis
- Developer Novartis; Vanda Pharmaceuticals
- Class Antipsychotics; Anxiolytics; Azabicyclo compounds; Behavioural disorder therapies; Bridged bicyclo compounds; Ethers; Nootropics; Pyridines; Small molecules; Toluenes
- Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Social phobia
- Phase II Cognition disorders; Drug-induced dyskinesia; Phobic disorders